Stockscreener 앱 받기
129.70
0.77%
-1.01
시간 외 거래:
129.70
Neurocrine Biosciences Inc 주식(NBIX)의 최신 뉴스
Wolfe Research initiates coverage of Neurocrine Biosciences (NBIX) with outperform recommendation - MSN
Neurocrine expects INGREZZA sales to reach up to $2.8B in 2026 amid CRENESSITY launch momentum - MSN
Truist lowers Neurocrine Biosciences, Inc.’s (NBIX) PT following 2026 outlook update - MSN
Neurocrine Biosciences promotes Andrew Ratz to operations chief By Investing.com - Investing.com South Africa
Neurocrine at Stifel CNS Forum: Growth and Strategic Focus - Investing.com
Transcript : Neurocrine Biosciences, Inc. Presents at Stifel 2026 Virtual CNS Forum, Mar-17-2026 04 - marketscreener.com
Neurocrine Biosciences (NBIX) CTO Ratz reports initial stock and option grants - Stock Titan
Neurocrine Biosciences promotes Andrew Ratz to operations chief - Investing.com
Neurocrine Biosciences promotes Andrew Ratz to chief technical operations officer - StreetInsider
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer - PR Newswire
Morgan Stanley Lifts PT on Neurocrine Biosciences (NBIX) to $150 From $148, Keeps Overweight Rating - MSN
Neurocrine Biosciences: The Song Remains The Same (NASDAQ:NBIX) - Seeking Alpha
Iron Triangle Partners LP Acquires New Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Distillate Capital Partners LLC Trims Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Boone Capital Management Decreases Stake in Neurocrine Biosciences - National Today
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Braidwell LP - MarketBeat
Boone Capital Management LLC Has $23.36 Million Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Assessing Neurocrine Biosciences (NBIX) Valuation After GARP Recognition And Reaffirmed Confidence In Ingrezza - simplywall.st
Dodge & Cox Decreases Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
2Xideas AG Trims Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Swiss National Bank Sells 14,100 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Top GARP Pick with Strong Growth and a Reasonable Price - ChartMill
Connor Clark & Lunn Investment Management Ltd. Acquires 32,480 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Given New $177.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Neurology stocks rebound in 2025 after midyear slump - bioworld.com
Magnetar Financial LLC Acquires New Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Korea Investment CORP Has $10.06 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
First Trust Advisors LP Has $50.97 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Capital Fund Management S.A. Has $17.37 Million Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Is It Time To Reassess Neurocrine Biosciences (NBIX) After The Recent Share Price Pullback - simplywall.st
A Look At Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Pullback - Yahoo Finance
Victory Capital Management Inc. Buys 31,981 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Cantor Fitzgerald Keeps Overweight on NBIX Neurocrine Biosciences March 2026 - Meyka
Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum - PR Newswire
Cantor Fitzgerald raises Neurocrine Bio price target on Ingrezza outlook By Investing.com - Investing.com Canada
Barclays Increases Stake in Neurocrine Biosciences - National Today
Neurocrine Biosciences, Inc. $NBIX Shares Bought by Barclays PLC - MarketBeat
American Century Companies Inc. Sells 52,349 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Transcript : Neurocrine Biosciences, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-09-2026 08 - marketscreener.com
The Technical Signals Behind (NBIX) That Institutions Follow - Stock Traders Daily
Rhenman & Partners Asset Management Trims Neurocrine Biosciences Stake - National Today
Rhenman & Partners Asset Management AB Sells 34,500 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
14,653 Shares in Neurocrine Biosciences, Inc. $NBIX Acquired by Munich Reinsurance Co Stock Corp in Munich - MarketBeat
What insider trading reveals about Neurocrine Biosciences Inc. stockM&A Rumor & Reliable Entry Point Alerts - Naître et grandir
Equifax Expands Data Solutions While Neurocrine Biosciences Advances Neurological Treatment Research - geneonline.com
Two stocks flagged for study: Equifax and Neurocrine Bio review - Stock Titan
Focus Partners Advisor Solutions LLC Buys 8,011 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX) CFO discloses bona fide gift of shares - Stock Titan
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Teachers Retirement System of The State of Kentucky - MarketBeat
GW&K Investment Management Trims Neurocrine Biosciences Stake - National Today
GW&K Investment Management LLC Sells 17,980 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Segall Bryant & Hamill LLC - MarketBeat
Neurocrine Biosciences Forms Death Cross, Signaling Potential Bearish Trend - Markets Mojo
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Strong Buy Ratings and 33.92% Potential Upside - DirectorsTalk Interviews
Neurocrine Biosciences, Inc. $NBIX Stock Position Lowered by TD Asset Management Inc - MarketBeat
Rafferty Asset Management LLC Sells 20,445 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Risk Check: Why is Neurocrine Biosciences Inc stock going up2025 Market Overview & Short-Term Trading Alerts - baoquankhu1.vn
DNB Asset Management AS Boosts Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
NBIX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus - Yahoo Finance UK
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Primecap Management Co. CA - MarketBeat
Neurocrine Biosciences Experiences Revision in Its Stock Evaluation Amid Strong Financial Metrics - Markets Mojo
9,887 Shares in Neurocrine Biosciences, Inc. $NBIX Bought by Fox Run Management L.L.C. - MarketBeat
Does Strong Q4 Results And INGREZZA Guidance Change The Bull Case For Neurocrine Biosciences (NBIX)? - simplywall.st
2.39%
1.75%
자본화:
|
볼륨(24시간):